Vaccitech, which owns the technology behind the AstraZeneca vaccine, warns that concerns about the side-effects of rare blood clots could hurt the royalty and affect the reputation of products in its pipeline.
Oxford University Spinout A released its prospectus on Friday Initial public offering At least $ 100 million for Nasdaq over the weekend in the US and several EU countries Proposed against Vaccinating young people.
The filing reveals how much the vaccine can take a start from sales. If and when AstraZeneca starts selling shots for profit in the aftermath of the epidemic – which they say could happen in early July 2021 – Oxford will pay about a quarter of the royalties from the vaccine VaxitechTotal sales accounted for about 1.4 percent.
The company received a অফ 2.5 million off-payment when it transferred the technology behind the Oxford / AstraZeneca vaccine last year.
Vaccitech is developing vaccines for other infectious diseases, including viruses behind shingles and MERS, other coronaviruses, as well as using the same vector technology to treat cancer and chronic hepatitis.
The epidemic has helped the company prove the work of its technology in millions of people, while many biotechs from clinical studies have come to light with little or no data. The rapid development and production of the Astragenica vaccine has also helped to prove that Vaccitech technology can be measured quickly.
But while the Oxford / AstraZeneca vaccine, known as AZD1222, has been shown to be safe and effective, recent concerns about very rare side-effects are now considering the public’s perception of the shot.
The agency wrote in the filing, “There is no guarantee that the vaccine is not involved in increasing the overall risk of thromboembolic events.
Vacicheck further warned that studies showing the Astrageneca vaccine against the first identified variant in South Africa would have less impact.
The latest coron virus news
Follow FT’s live coverage and analysis of global epidemics and fast-growing economic crises Here.
“Any association of AZD1222 with adverse events, or the perception of such an organization, or any result that AZD1222 is less effective than certain types of Covid-19, may reduce sales of AZD1222 and therefore potential payments that we make on net sales.” Vaccines, and otherwise any of our products could adversely affect our ability to develop and commercialize candidates, “it said.
The decision to enroll in New York is a disappointment for the UK, which expects more investment in life sciences. According to people close to the situation, the UK Treasury has a part of this company.
The largest investor is Oxford Sciences Innovation, an early-stage venture capital firm focused on the commercialization of intellectual property from universities, with 29 per cent stakeholders ahead of the offer. Other large shareholders include Bima Bima Prudential and authorized firms with Google Ventures with a 13 per cent stake, which holds 6 per cent.